HLA-DRB5 Rabbit Polyclonal Antibody
Specifications
| Product Data | |
| Application | IHC |
|---|---|
| Recommended Dilution | IHC: 40-200 Positive control: Human liver cancer Predicted cell location: Cytoplasm and Cell membrane |
| Reactivity | Human |
| Antibody Host | Rabbit |
| Isotype | IgG |
| Clonality | Polyclonal |
| Immunogen | Fusion protein of human HLA-DRB5 |
| Buffer | pH7.4 PBS, 0.05% NaN3, 40% Glycerol |
| Concentration | lot specific |
| Purification | Antigen affinity purification |
| Conjugation | Unconjugated |
| Storage | Store at -20°C. |
| Stability | 1 year |
| Shipping | Blue Ice |
| Gene Name | major histocompatibility complex, class II, DR beta 5 |
| Database Link | |
| Background | HLA-DRB5 belongs to the HLA class II beta chain paralogues. This class II molecule is a heterodimer consisting of an alpha (DRA) and a beta (DRB) chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa and its gene contains 6 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, exon 4 encodes the transmembrane domain and exon 5 encodes the cytoplasmic tail. Within the DR molecule the beta chain contains all the polymorphisms specifying the peptide binding specificities. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. DRB1 is expressed at a level five times higher than its paralogues DRB3, DRB4 and DRB5. The presence of DRB5 is linked with allelic variants of DRB1, otherwise it is omitted. There are 4 related pseudogenes: DRB2, DRB6, DRB7, DRB8 and DRB9. |
| Reference Data | |
| Protein Categories | Cancer: Haematopoietic and Lymphoid, Membrane Proteins |
Reviews
Documents
| Product Manuals |
| FAQs |
| SDS |
Citations
Single-cell RNA sequencing analysis to explore immune cell heterogeneity and novel biomarkers for the prognosis of lung adenocarcinoma
Xu, Wang, Liang et al
Front Genet (2022) 13, 975542 DOI: 10.3389/fgene.2022.975542
Xu, Wang, Liang et al
Front Genet (2022) 13, 975542 DOI: 10.3389/fgene.2022.975542
Cited by 14
AI Summary: In this study, OriGene’s HLA-DRB5 and CCDC50 qPCR primers and antibodies were used to experimentally validate the expression of novel biomarker genes identified by single-cell RNA sequencing and prognostic modeling in lung adenocarcinoma.
Snippet: … Method: We first reduced the dimensionality of the GSE149655 single-cell data. …Results: The single-cell dataset GSE149655 was subjected to quality control, filtration and dimensionality reduction. …Two new molecular markers related to LUAD, HLA-DRB5 and CCDC50, were verified by qPCR and immunohistochemistry. The results showed that HLA-DRB5 expression was negatively correlated with the risk of LUAD, and CCDC50 expression was positively correlated with the risk of LUAD. Conclusion: Therefore, we identified a prognostic risk model including CCL20, CP, HLA-DRB5, RHOV, CYP4B1, BASP1, ACSL4, GNG7, CCDC50 and SPATS2 as risk biomarkers and verified their predictive value for the prognosis of LUAD, which could serve as a new therapeutic target.Copyright 2022 Xu, Wang, Liang and Song
Showing 1-1 of 1 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen
complexities in the preparation of your product. International customers may expect an additional 1-2 weeks
in shipping.
Related Products
- Price:
- Actual Price:
Welcome to OriGene AI!
I'm your AI-powered guide to everything OriGene.
Ask me anything:
- Product specs
- Ordering help
- Technical questions
- How to find exactly what your experiment needs
Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.
